Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure
- 83 Downloads
In an attempt to reduce the heart failure epidemic, screening and prevention will become an increasing focus of management in the wider at-risk population. Refining risk prediction through the use of biomarkers in isolation or in combination is emerging as a critical step in this process. The utility of biomarkers to identify disease manifestations before the onset of symptoms and detrimental myocardial damage is proving to be valuable. In addition, biomarkers that predict the likelihood and rate of disease progression over time will help streamline and focus clinical efforts and therapeutic strategies. Importantly, several recent early intervention studies using biomarker strategies are promising and indicate that not only can new-onset heart failure be reduced but also the development of other cardiovascular conditions.
KeywordsBiomarkers Heart failure Cardiovascular disease prediction and prevention
This work was supported by the European Commission FP7 project FIBRO-TARGETS and HOMAGE and the Health Research Board of Ireland [grant numbers 602904; 305507; CSA-2012-36, respectively].
Compliance with Ethics Guidelines
Conflict of Interest
Chris Watson, Mark Ledwidge, Ken McDonald and Joe Gallagher have no relevant disclosures to report.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.Phelan D, Watson CJ, Martos R, et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One. 2012;7(11).Google Scholar
- 9.Seliger S, de Lemos J, Neeland I, et al. Older adults, “malignant” left ventricular hypertrophy and associated cardiac specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure—JACC Heart Failure 2015 (in press).Google Scholar
- 10.•Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress. Framingham Heart Study Circ. 2012;126:1596–604. This important paper highlights that the value of measuring cardiovascular stress biomarkers in adding prognostic value to standard risk factors for predicting death, overall cardiovascular events, and heart failure.CrossRefGoogle Scholar
- 21.•Browers FP, van Gilst WH, Dammen K, et al. Clinical risk stratification optimises value of biomarkers to predict new-onset heart failure in a community based cohort. Circ Heart Fail. 2014;7:723–31. This is an important paper highlighting a multi-marker approach to risk stratify patients in the prediction of new onset heart failure.CrossRefGoogle Scholar
- 27.•Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66–74. This study provides the first evidence that natriuretic peptide screening and collaborative of patients at risk of heart failure can reduce the combined rates of left ventricular systolic dysfunction, diastolic dysfunction, and heart failure.CrossRefPubMedGoogle Scholar
- 30.Davis ME, Richards M, Nicholls G, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type natriuretic peptides in mild stable heart failure. 2006;113:977–85.Google Scholar